trans crocetin liposomal (LEAF-4L6715)
/ Leaf 4 Life, Strasbourg Europe Cancer Institute, University Hospitals of Strasbourg
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
October 16, 2024
Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome
(clinicaltrials.gov)
- P3 | N=310 | Not yet recruiting | Sponsor: LEAF4Life, Inc.
New P3 trial • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases
December 16, 2021
A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes
(clinicaltrials.gov)
- P1/2; N=37; Completed; Sponsor: Institut de cancérologie Strasbourg Europe; Recruiting ➔ Completed; N=90 ➔ 37; Trial completion date: Jun 2022 ➔ Aug 2021; Trial primary completion date: Jun 2022 ➔ Aug 2021
Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • Septic Shock
August 25, 2021
A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes
(clinicaltrials.gov)
- P1/2; N=90; Recruiting; Sponsor: Institut de cancérologie Strasbourg Europe; Trial completion date: Jun 2021 ➔ Jun 2022; Trial primary completion date: Jun 2021 ➔ Jun 2022
Clinical • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • Septic Shock
February 02, 2021
A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes
(clinicaltrials.gov)
- P1/2; N=90; Recruiting; Sponsor: Institut de cancérologie Strasbourg Europe; Trial completion date: Dec 2020 ➔ Jun 2021; Trial primary completion date: Dec 2020 ➔ Jun 2021
Clinical • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Septic Shock
October 19, 2020
A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes
(clinicaltrials.gov)
- P1/2; N=90; Recruiting; Sponsor: Institut de Cancerologie Strasbourg Europe; N=180 ➔ 90
Clinical • Enrollment change • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Septic Shock
September 04, 2020
LEAF-4L6715: A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease (LEAF-4L7520/4L6715)
(clinicaltrials.gov)
- P1/2; N=180; Recruiting; Sponsor: Institut de Cancerologie Strasbourg Europe; Trial primary completion date: Jul 2020 ➔ Dec 2020
Clinical • Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 6
Of
6
Go to page
1